Volume Alert - INO 10.04 Inovio Pharmaceuticals $INO Hit a high today of 10.35 Closing the day 10:29 at 10.04 -0.96 -8.73% With a day low of 9.51 and a total volume of 1,238,983.
INO Recent Posts: http://investorshangout.com/Inovio-Pharmaceut...INO-56788/
INO Inovio Pharmaceuticals Recent Headline News
Inovio Pharmaceuticals (INO) Stock Drops Following Roche Collaboration Termination
at The Street - 1 hr 16 mins ago
Shares of Inovio Pharmaceuticals (INO) fell Monday after the company announced Roche (RHHVF) had terminated its collaboration, option, and license agreement to develop Inovio's prostate cancer immunotherapy INO-5150.
INO: 9.94 (-1.06)
Aethlon Medical up on successful Ebola treatment
Seeking Alpha - at Seeking Alpha - 1 hr 41 mins ago
BCRX: 10.26 (+0.19), VSR: 2.96 (-0.03), TKMR: 17.10 (+0.69), NNVC: 3.29 (-0.10), INO: 9.94 (-1.06), CMRX: 33.72 (+1.48), APT: 2.89 (-0.03), HEB: 0.27 (unch), SRPT: 15.23 (-0.09), SMED: 4.26 (-0.12), NLNK: 31.48 (+0.94), PLX: 2.05 (-0.04), LAKE: 11.05 (-0.01), NSPH: 0.44 (unch)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:15AM CST
CADC: 5.65 (+1.39), INO: 9.94 (-1.06), CLDX: 19.13 (+4.97), HAL: 49.60 (-5.48), ROX: 1.86 (-0.12), SNSS: 2.32 (+0.65), DNR: 9.93 (-1.27), DWA: 22.25 (-3.77), GSAT: 2.83 (-0.14), CMGE: 24.88 (-0.72), FOLD: 6.72 (+1.03), BHI: 66.10 (+6.21)
Inovio down on termination of Roche collaboration
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:07AM CST
INO: 9.94 (-1.06)
Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy
PR Newswire - Mon Nov 17, 2:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the company and Roche have terminated their 2013 collaboration, option, and license agreement to co-develop INO-5150, Inovio's DNA immunotherapy targeting prostate cancer, as well as their research collaboration in prostate cancer. All of Roche's rights to INO-5150, including the right to license the product to other parties, will be returned to Inovio. Inovio plans to independently advance INO-5150 into a phase I clinical trial in the first half of 2015.
INO: 9.94 (-1.06)
Global Ebola Viral Infections Clinical Trials Report H2, 2014 - Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 4:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/wtw3b6/ebola_viral) has announced the addition of the "Ebola Viral Infections Global Clinical Trials Review, H2, 2014" report to their offering. Ebola Viral Infections Global Clinical Trials Review, H2, 2014" provides data on the Ebola Viral Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ebola Viral Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ebola Viral Infections. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Tekmira Pharmaceuticals Corp. - Sarepta Therapeutics, Inc. - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Chimerix, Inc. Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Academy of Military Medical Sciences - University of Oxford For more information visit http://www.researchandmarkets.com/research/wt...bola_viral
INO: 9.94 (-1.06), CMRX: 33.72 (+1.48), SRPT: 15.23 (-0.09), TKMR: 17.10 (+0.69), GSK: 45.98 (+0.24)
Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Nov 12, 4:20AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday November 11. CEO Interview: Bill Tauscher, Blackhawk (NASDAQ: HAWK ). Other stocks mentioned: Safeway (NYSE: SWY ) Blackhawk ( HAWK ) is a leading global...
WFM: 47.55 (+0.44), DHI: 24.53 (+0.15), AMZN: 321.82 (-6.00), TSLA: 254.59 (-4.09), KR: 58.03 (+0.32), SWY: 34.76 (-0.09), CLX: 100.82 (+0.70), XOM: 94.95 (-0.14), FCAU: 12.45 (+0.05), INO: 9.94 (-1.06), WHR: 176.91 (+3.64), T: 35.86 (-0.04), ISIS: 49.07 (+0.06), VALE: 8.84 (-0.03), EOG: 96.63 (-1.53), HAWK: 36.25 (-0.22), SHW: 240.20 (+0.55), VZ: 51.41 (-0.09), TOL: 33.95 (+0.23), REGN: 402.91 (+7.71), KELYA: 15.04 (-0.38), BABA: 114.21 (-0.89)
Inovio to Present at Upcoming Investor Conferences
PR Newswire - Tue Nov 11, 5:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that Dr. J. Joseph Kim, President & CEO, will present a corporate overview at the upcoming Stifel Healthcare Conference, Brean Capital Life Science Conference, and Piper Jaffray Healthcare Conference in New York, NY.
INO: 9.94 (-1.06)
Inovio Pharmaceuticals' (INO) CEO Joseph Kim on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 12:14PM CST
INO: 9.94 (-1.06)
Inovio lowers net loss by 77% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:06AM CST
INO: 9.94 (-1.06)
4 Stocks to Look at via Ebola Crisis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 9:43AM CST
Here are four stocks poised to benefit from bringing treatment for the dreaded virus Ebola.
MMM: 158.97 (+0.12), BCRX: 10.26 (+0.19), TK: 54.13 (-0.08), CCL: 41.42 (-0.08), DAL: 43.89 (+0.14), KMB: 113.86 (+1.21), DIS: 90.37 (-0.43), JBLU: 12.44 (-0.16), GSK: 45.98 (+0.24), MAR: 77.45 (-0.51), UAL: 56.84 (+0.74), LUV: 39.39 (+0.44), INO: 9.94 (-1.06), JNJ: 108.29 (+0.13), RCL: 68.56 (-1.01), APT: 2.89 (-0.03)
Technical Pulse on Biotech Stocks - Dendreon, Alkermes, Exact Sciences, Inovio Pharma, and Seattle Genetics
PR Newswire - Mon Nov 10, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Dendreon Corporation (NASDAQ: DNDN), Alkermes PLC (NASDAQ: ALKS), Exact Sciences Corporation (NASDAQ: EXAS), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Seattle Genetics Inc. (NASDAQ: SGEN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, November 07, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,573.93, up 0.11% and the NASDAQ Composite closed at 4,632.53, down 0.13%. The S&P 500 finished the session 0.03% higher at 2,031.92. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 775.27, down 0.94%, whereas the index has gained 10.75% in the previous three months. Register for your complimentary reports on these five stocks at:
INO: 9.94 (-1.06), SGEN: 35.91 (+0.55), DNDN: 0.16 (+0.05), EXAS: 23.05 (+0.05), ALKS: 52.09 (+0.62)
Inovio Pharmaceuticals beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 5:59AM CST
INO: 9.94 (-1.06)
Inovio posts 3Q loss
Automated Insights - Mon Nov 10, 5:15AM CST
SAN DIEGO (AP) _ Inovio Pharmaceuticals Inc. (INO) on Monday reported a loss of $7.2 million, or 12 cents per share, in its third quarter.
INO: 9.94 (-1.06)
Inovio Pharmaceuticals Reports 2014 Third Quarter Financial Results
PR Newswire - Mon Nov 10, 5:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today reported financial results for the quarter ended September 30, 2014.
INO: 9.94 (-1.06)
Will Inovio (INO) Disappoint Expectations for Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:35PM CST
Inovio (INO), which is scheduled to report third-quarter results on Nov 10, had delivered a negative earnings surprise of 11.76% in the last quarter.
MACK: 8.78 (+0.30), MNK: 88.44 (+0.33), INO: 9.94 (-1.06)
Inovio reports November 10
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 10:57AM CST
INO: 9.94 (-1.06)
Inovio Pharmaceuticals to Report Third Quarter 2014 Financial Results on November 10, 2014
PR Newswire - Tue Nov 04, 5:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it will host a conference call and live webcast to report its third quarter 2014 financial results on Monday, November 10, 2014, at 8:00 a.m. ET. Management will discuss third quarter earnings and expectations for the current and upcoming quarters.
INO: 9.94 (-1.06)
Critical Alerts For Mobileye NV, Schlumberger, Ambarella, Walter Energy and Inovio Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Nov 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for MBLY, SLB, AMBA, WLT and INO.
AMBA: 48.60 (+0.76), INO: 9.94 (-1.06), WLT: 3.02 (+0.08), MBLY: 47.26 (-0.17), SLB: 96.24 (+0.92)
The most undervalued, yet comprehensive cancer immunotherapy in development?
ACCESSWIRE - Mon Nov 03, 7:03AM CST
Los Angeles, CA / ACCESSWIRE / November 3, 2014 / The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
INO: 9.94 (-1.06), NWBO: 5.49 (-0.30), DNDN: 0.16 (+0.05), GALE: 1.83 (-0.04)
INO Recent Posts: http://investorshangout.com/Inovio-Pharmaceut...INO-56788/
INO Inovio Pharmaceuticals Recent Headline News
Inovio Pharmaceuticals (INO) Stock Drops Following Roche Collaboration Termination
at The Street - 1 hr 16 mins ago
Shares of Inovio Pharmaceuticals (INO) fell Monday after the company announced Roche (RHHVF) had terminated its collaboration, option, and license agreement to develop Inovio's prostate cancer immunotherapy INO-5150.
INO: 9.94 (-1.06)
Aethlon Medical up on successful Ebola treatment
Seeking Alpha - at Seeking Alpha - 1 hr 41 mins ago
BCRX: 10.26 (+0.19), VSR: 2.96 (-0.03), TKMR: 17.10 (+0.69), NNVC: 3.29 (-0.10), INO: 9.94 (-1.06), CMRX: 33.72 (+1.48), APT: 2.89 (-0.03), HEB: 0.27 (unch), SRPT: 15.23 (-0.09), SMED: 4.26 (-0.12), NLNK: 31.48 (+0.94), PLX: 2.05 (-0.04), LAKE: 11.05 (-0.01), NSPH: 0.44 (unch)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:15AM CST
CADC: 5.65 (+1.39), INO: 9.94 (-1.06), CLDX: 19.13 (+4.97), HAL: 49.60 (-5.48), ROX: 1.86 (-0.12), SNSS: 2.32 (+0.65), DNR: 9.93 (-1.27), DWA: 22.25 (-3.77), GSAT: 2.83 (-0.14), CMGE: 24.88 (-0.72), FOLD: 6.72 (+1.03), BHI: 66.10 (+6.21)
Inovio down on termination of Roche collaboration
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:07AM CST
INO: 9.94 (-1.06)
Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy
PR Newswire - Mon Nov 17, 2:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the company and Roche have terminated their 2013 collaboration, option, and license agreement to co-develop INO-5150, Inovio's DNA immunotherapy targeting prostate cancer, as well as their research collaboration in prostate cancer. All of Roche's rights to INO-5150, including the right to license the product to other parties, will be returned to Inovio. Inovio plans to independently advance INO-5150 into a phase I clinical trial in the first half of 2015.
INO: 9.94 (-1.06)
Global Ebola Viral Infections Clinical Trials Report H2, 2014 - Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 4:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/wtw3b6/ebola_viral) has announced the addition of the "Ebola Viral Infections Global Clinical Trials Review, H2, 2014" report to their offering. Ebola Viral Infections Global Clinical Trials Review, H2, 2014" provides data on the Ebola Viral Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ebola Viral Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ebola Viral Infections. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Tekmira Pharmaceuticals Corp. - Sarepta Therapeutics, Inc. - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Chimerix, Inc. Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Academy of Military Medical Sciences - University of Oxford For more information visit http://www.researchandmarkets.com/research/wt...bola_viral
INO: 9.94 (-1.06), CMRX: 33.72 (+1.48), SRPT: 15.23 (-0.09), TKMR: 17.10 (+0.69), GSK: 45.98 (+0.24)
Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Nov 12, 4:20AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday November 11. CEO Interview: Bill Tauscher, Blackhawk (NASDAQ: HAWK ). Other stocks mentioned: Safeway (NYSE: SWY ) Blackhawk ( HAWK ) is a leading global...
WFM: 47.55 (+0.44), DHI: 24.53 (+0.15), AMZN: 321.82 (-6.00), TSLA: 254.59 (-4.09), KR: 58.03 (+0.32), SWY: 34.76 (-0.09), CLX: 100.82 (+0.70), XOM: 94.95 (-0.14), FCAU: 12.45 (+0.05), INO: 9.94 (-1.06), WHR: 176.91 (+3.64), T: 35.86 (-0.04), ISIS: 49.07 (+0.06), VALE: 8.84 (-0.03), EOG: 96.63 (-1.53), HAWK: 36.25 (-0.22), SHW: 240.20 (+0.55), VZ: 51.41 (-0.09), TOL: 33.95 (+0.23), REGN: 402.91 (+7.71), KELYA: 15.04 (-0.38), BABA: 114.21 (-0.89)
Inovio to Present at Upcoming Investor Conferences
PR Newswire - Tue Nov 11, 5:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that Dr. J. Joseph Kim, President & CEO, will present a corporate overview at the upcoming Stifel Healthcare Conference, Brean Capital Life Science Conference, and Piper Jaffray Healthcare Conference in New York, NY.
INO: 9.94 (-1.06)
Inovio Pharmaceuticals' (INO) CEO Joseph Kim on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 12:14PM CST
INO: 9.94 (-1.06)
Inovio lowers net loss by 77% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:06AM CST
INO: 9.94 (-1.06)
4 Stocks to Look at via Ebola Crisis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 9:43AM CST
Here are four stocks poised to benefit from bringing treatment for the dreaded virus Ebola.
MMM: 158.97 (+0.12), BCRX: 10.26 (+0.19), TK: 54.13 (-0.08), CCL: 41.42 (-0.08), DAL: 43.89 (+0.14), KMB: 113.86 (+1.21), DIS: 90.37 (-0.43), JBLU: 12.44 (-0.16), GSK: 45.98 (+0.24), MAR: 77.45 (-0.51), UAL: 56.84 (+0.74), LUV: 39.39 (+0.44), INO: 9.94 (-1.06), JNJ: 108.29 (+0.13), RCL: 68.56 (-1.01), APT: 2.89 (-0.03)
Technical Pulse on Biotech Stocks - Dendreon, Alkermes, Exact Sciences, Inovio Pharma, and Seattle Genetics
PR Newswire - Mon Nov 10, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Dendreon Corporation (NASDAQ: DNDN), Alkermes PLC (NASDAQ: ALKS), Exact Sciences Corporation (NASDAQ: EXAS), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Seattle Genetics Inc. (NASDAQ: SGEN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, November 07, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,573.93, up 0.11% and the NASDAQ Composite closed at 4,632.53, down 0.13%. The S&P 500 finished the session 0.03% higher at 2,031.92. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 775.27, down 0.94%, whereas the index has gained 10.75% in the previous three months. Register for your complimentary reports on these five stocks at:
INO: 9.94 (-1.06), SGEN: 35.91 (+0.55), DNDN: 0.16 (+0.05), EXAS: 23.05 (+0.05), ALKS: 52.09 (+0.62)
Inovio Pharmaceuticals beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 5:59AM CST
INO: 9.94 (-1.06)
Inovio posts 3Q loss
Automated Insights - Mon Nov 10, 5:15AM CST
SAN DIEGO (AP) _ Inovio Pharmaceuticals Inc. (INO) on Monday reported a loss of $7.2 million, or 12 cents per share, in its third quarter.
INO: 9.94 (-1.06)
Inovio Pharmaceuticals Reports 2014 Third Quarter Financial Results
PR Newswire - Mon Nov 10, 5:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today reported financial results for the quarter ended September 30, 2014.
INO: 9.94 (-1.06)
Will Inovio (INO) Disappoint Expectations for Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:35PM CST
Inovio (INO), which is scheduled to report third-quarter results on Nov 10, had delivered a negative earnings surprise of 11.76% in the last quarter.
MACK: 8.78 (+0.30), MNK: 88.44 (+0.33), INO: 9.94 (-1.06)
Inovio reports November 10
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 10:57AM CST
INO: 9.94 (-1.06)
Inovio Pharmaceuticals to Report Third Quarter 2014 Financial Results on November 10, 2014
PR Newswire - Tue Nov 04, 5:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it will host a conference call and live webcast to report its third quarter 2014 financial results on Monday, November 10, 2014, at 8:00 a.m. ET. Management will discuss third quarter earnings and expectations for the current and upcoming quarters.
INO: 9.94 (-1.06)
Critical Alerts For Mobileye NV, Schlumberger, Ambarella, Walter Energy and Inovio Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Nov 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for MBLY, SLB, AMBA, WLT and INO.
AMBA: 48.60 (+0.76), INO: 9.94 (-1.06), WLT: 3.02 (+0.08), MBLY: 47.26 (-0.17), SLB: 96.24 (+0.92)
The most undervalued, yet comprehensive cancer immunotherapy in development?
ACCESSWIRE - Mon Nov 03, 7:03AM CST
Los Angeles, CA / ACCESSWIRE / November 3, 2014 / The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
INO: 9.94 (-1.06), NWBO: 5.49 (-0.30), DNDN: 0.16 (+0.05), GALE: 1.83 (-0.04)
